

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/534,081
Filing Date	May 5, 2005
First Named Inventor	K. Fukatsu
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3119 USOP

Sheet 1 of 3

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
J.C./ Change(s) applied to document L.A.S. 3/22/2009		US- 6,867,320	03-15-2005	Asahi Kasei Pharma Corporation	Shoda et al.
		US- 2004/0058965	03-25-2004	Takeda Pharmaceuticals NA	Monose et al.
		US- 2005/0089866	04-28-2005	S. Hinuma et al.	
		US- 2004/0137517	07-15-2004	J. Leon et al.	
		US- 6,710,063	03-23-2004	SmithKline Beecham Corporation	Chao et al.
		US- 6,723,740	04-20-2004	SmithKline Beecham Corporation	Chao et al.
		US- 6,294,580	09-25-2001	Glaxo Wellcome Inc.	Wilson et al.
		US- 6,555,577	04-29-2003	Novo Nordisk A/S	Mogensen et al.
		US- 6,867,218	03-15-2005	Novo Nordisk A/S	Mogensen et al.
		US- 2004/0157890	08-12-2004	P. Beswick et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
J.C./		WO 03/070686 (Abstract Only)	08-28-2003	Asahi Kasei Kabushiki		✓
J.C./		WO 2003/099793	12-04-2003	Takeda Pharmaceutical Co.		
J.C./		WO 03/016254 (Abstract Only)	02-27-2003	Ono Pharmaceutical Co.		✓
J.C./		WO 02/053547 (Abstract Only)	07-11-2002	Takeda Chemical Industries		✓
J.C./		WO 02/057783	07-25-2002	Glaxo Group Limited		
J.C./		WO 03/068959 (Abstract Only)	08-21-2003	Takeda Chemical Industries		✓

Examiner
Signature

/Jean Cornet/

Date
Considered

09/16/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.